Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
WALTHAM, Mass., May 01, 2018 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Bank of America Merrill Lynch 2018 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 15, 2018. Tim Pearson, EVP and CFO of TESARO, will participate in an analyst-led moderated Q&A at 4:20 PM PT and in meetings with investors.
- The Leerink Boston Biopharma Bus Tour on Thursday, May 17, 2018. Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications and Investor Relations
+1.781.325.1116 or [email protected]
Kate Rausch
Associate Director, Investor Relations
1.781-257-2505 or [email protected]
